BioPharmSignal logoBioPharmSignal

Biotech News

Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

Phathom Pharmaceuticals (PHAT)Phathom PharmaceuticalsEarnings

Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)

Related news

PHATPhathom Pharmaceuticals2026-07-30 10:59 EST

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

PHATPhathom Pharmaceuticals2026-04-30 10:59 EST

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

Phathom Pharmaceuticals

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive...

Recent company news

PHATPhathom Pharmaceuticals2026-10-23 08:00 EST

Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA

PHATPhathom Pharmaceuticals2026-10-19 12:00 EST

Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

PHATPhathom Pharmaceuticals2026-10-12 12:00 EST

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

PHATPhathom Pharmaceuticals2026-10-08 12:00 EST

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

PHATPhathom Pharmaceuticals2026-09-29 12:00 EST

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Stock data

Close
7.01 USD
Market cap
769.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States